Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Income from Continuing Operations (2016 - 2026)

Protara Therapeutics' Income from Continuing Operations history spans 14 years, with the latest figure at 17973000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 42.99% to 17973000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 65507000.0 through Mar 2026, down 38.43% year-over-year, with the annual reading at 59526000.0 for FY2025, 29.89% down from the prior year.
  • Income from Continuing Operations came in at 17973000.0 for Q1 2026, up from 18913000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 7691000.0 in Q3 2022 to a low of 38877000.0 in Q4 2022.
  • The 5-year median for Income from Continuing Operations is 11219000.0 (2024), against an average of 13525882.35.
  • Year-over-year, Income from Continuing Operations tumbled 280.1% in 2022 and then surged 73.71% in 2023.
  • Protara Therapeutics' Income from Continuing Operations stood at 38877000.0 in 2022, then soared by 73.71% to 10221000.0 in 2023, then plummeted by 36.98% to 14001000.0 in 2024, then crashed by 35.08% to 18913000.0 in 2025, then increased by 4.97% to 17973000.0 in 2026.
  • Per Business Quant, the three most recent readings for TARA's Income from Continuing Operations are 17973000.0 (Q1 2026), 18913000.0 (Q4 2025), and 13258000.0 (Q3 2025).